GSK

We’re proud to have retained our position on the CDP A List for Climate Change and Water for 2025. These ratings reflect the progress we’re making toward our climate and nature targets, helping to build a more resilient supply chain, support long-term business growth, and protect human health. Learn more about our approach here: https://gsk.to/4iPi4dj

#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: https://gsk.to/4rIw4JL

That’s a wrap on #ASH25! We had fantastic time in Orlando meeting with colleagues and industry experts and sharing more about how we're innovating to improve outcomes for people living with blood cancer. Hear from Nina Mojas and Ali Çimen as they share their reflections. 🔗 Read real patient experiences and discover how we’re advancing care for myeloma and myelofibrosis: https://gsk.to/4pUPae2

Outsmarting cancer demands focus. At GSK, we’re channelling our science and tech where we can make the biggest difference for people living with cancer. Our oncology leaders, Hesham A. Abdullah, MD, MSc, Nina Mojas and Ali Çimen are at #ASH25 this weekend sharing more about our ongoing research and bold vision to transform cancer care. 🔗 Find out how we’re getting ahead of cancer: https://gsk.to/48oIk9y

We’ve touched down at #ASH25! Hear from Hesham Abdullah as he shares our focus for this year’s annual meeting - and follow us for more updates and insights. 🔗 Read more about Hesham’s ambitions for improving outcomes in cancer care: https://gsk.to/3XC9KE3

Cancer remains one of the world’s leading causes of death – yet people living with difficult-to-treat blood cancers still face limited treatment options. We’re working to change that. By combining targeted science with innovative technology, our goal is simple – to help people with blood cancer live longer, fuller lives. Learn more: https://gsk.to/3KBRoQv #ASH25

An application to list a respiratory syncytial virus (RSV) vaccine against lower respiratory tract disease caused by RSV is being reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2026. The submission is requesting a listing for adults aged 60-74 years to be reimbursed on the National Immunisation Programme (NIP). As part of the PBAC review process, individuals and families affected by RSV are invited to share their perspectives. Have your say before 21 January 2026 here: https://lnkd.in/gRmKsNMb This content is for informational purposes only. Always consult a qualified healthcare professional for guidance.

Today marks a significant milestone for GSK's ongoing commitment to innovation in the U.S.! We're proud to announce the opening of our expanded space at Cambridge Park Drive, which will serve as our new U.S. headquarters for Vaccine & Infectious Disease Research & Development. Located in Boston's vibrant innovation hub, this facility underscores our dedication to accelerating the discovery and development of innovative medicines and vaccines. It's a key part of our substantial 5-year investment in U.S. R&D and manufacturing, enabling us to leverage advanced technologies, and create new, highly skilled jobs to deliver better, faster innovation for patients worldwide.

Clinical trials are the bridge between scientific discovery and potentially life-changing cancer treatments, but the complexity of some trials can place a high burden on patients. We want to put patients at the centre of our clinical trial design by making them available to more people, reducing unnecessary requirements and simplifying the enrolment process. Read more in our recent article: https://gsk.to/3XhUUlP

At GSK, we believe in the power of inclusion. Today, on #InternationalDayOfPersonsWithDisabilities, we're proud to highlight our commitment to creating a workplace where everyone is supported to thrive and be their best. We know that an inclusive and accessible environment drives better performance and innovation, helping us to make a greater impact on patients' lives. Find out more: https://gsk.to/4ozEiB3 #IDPwD #DisabilityInclusion